- Report
- May 2026
- 262 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 409 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 472 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 462 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 192 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 375 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 382 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 135 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 382 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 381 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 279 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 390 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 236 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 180 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 495 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 486 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 148 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 183 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 617 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- May 2026
- 493 Pages
Global
From €5210EUR$5,850USD£4,543GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more